The End-of-Phase 2 meeting resulted in alignment with the FDA on the proposed Phase 3 study design, including the inclusion/exclusion criteria, primary and secondary efficacy objectives, definition of ...
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation ... this news release contains forward-looking ...
Mr. Kenyon has served as the Company’s Chief Financial Officer and Secretary since September 2015. He has been a member of Outlook Therapeutics’ board of directors since August 2018 and also served as ...
To schedule a one-on-one meeting with Biofrontera, you may submit your request online via the registration link provided. To register for the conference, please visit ...